The 2017 Request for Application (RFA) is now open.
We are inviting competitive Letters of Intent (LOIs) that outline research with the potential to transform our understanding of NETs and/or lead to improved treatments and diagnostics for patients. LOIs may focus on any type of NET and may propose basic, translational, or clinical cancer research. We welcome multidisciplinary groups combining not only expertise in basic, translational, or clinical research, but also in biotechnology and nanotechnology, or other relevant disciplines. Proposals that cover promising and potentially transferable mechanisms and/or technologies, which have been applied successfully to other areas of cancer research, are highly desirable and will be evaluated based on their level of applicability to NETs.
Some areas of interest include but are not limited to: application of existing or new technologies to study, understand and target NETs – the immune microenvironment, nanotherapies – clinical, correlative, adaptive studies – nuclear medicine, theranostics, imaging – metastasis drivers, biomarkers.
We will award:
- At least one 4-year Accelerator award in the amount of $1,200,000 ($300K/year).
- At least one 2-year Petersen Investigator award in the amount of $300,000 ($150K/year).
- One to three 1-year Pilot Project awards not to exceed $100,000 ($50K-100K/year).
The deadline for submitting a competitive LOI is September 5, 2017.
The Nuclear Medicine Pilot Research Grant in Neuroendocrine Tumors (NETS) is open
Offered in collaboration with the Education and Research Foundation (ERF) of the Society of Nuclear Medicine and Molecular Imaging.
The Nuclear Medicine Pilot Research Grant in neuroendocrine tumors (NETs) is designed to help a basic or clinical scientist in the early stages of his/her career conduct novel and innovative research that may be leveraged to lead to further funding from other foundations, corporations or government agencies.
The grant will provide $50,000 for a one-year award. Funds will be directed to the sponsoring institution. Funds may be used to support the salary of the applicant, research costs, and/or travel. Indirect expenses are capped at 5%.
The deadline for submitting applications is September 29, 2017 by 5:00 p.m. E.D.T. U.S.
Learn More and ApplyWe are currently not accepting applications for the cell line prize.
Please visit our site in autumn for an update.
The lack of well-validated and widely accepted cell lines derived from intestinal carcinoid and pancreatic neuroendocrine tumors (PNET) is a significant barrier for research and development of new therapies. The Neuroendocrine Tumor Research Foundation therefore wishes to stimulate a concerted effort to create a “collection” of well-characterized cell lines that faithfully replicate tumor characteristics and genetics. The Foundation has partnered with the Rare Cancer Research Foundation (RCRF), a foundation dedicated to curing rare cancers through strategic investments and innovative collaborations, and the American Type Culture Collection (ATCC), the world’s largest non-profit cell line repository, to establish a Neuroendocrine Tumor Cell Line collection in their catalog. This challenge requires written documentation, detailed description of each cell line, and sample delivery.
